Stem cells therapies for liver diseases: for current practice and future goals.
Xie Y., Zhang Z., Pan Y., Wang FS.
Clinical Trial, published in Hepatol Int (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Hepatol Int (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40553243
- DOI
- 10.1007/s12072-025-10835-1
Abstract (original English)
Stem cell therapy has emerged as a promising approach for treating severe chronic liver diseases, including decompensated liver cirrhosis (DLC) and liver failure(LF), with mesenchymal stem cells (MSCs) being the most extensively investigated cell type in both preclinical and clinical trials. To summarize the research progress in clinical studies of stem cells therapy for chronic liver diseases, providing a comprehensive overview of current knowledge. Research on stem cell therapy for liver diseases was searched from databases such as PubMed, Web of Science, Google Scholar, and ClinicalTrials.gov. As of March 31, 2025, over 110 clinical trials investigating stem cell therapies for chronic liver diseases have been registered, predominantly in Phase I and Phase II stages. MSCs derived from umbilical cord, bone marrow, or adipose tissue representing the primary cellular sources. Stem cell therapy has demonstrated favorable safety profiles in the treatment of liver diseases. Concurrently, emerging evidence highlights its preliminary efficacy in enhancing patient survival rates and promoting hepatic functional recovery. However, challenges remain, such as inconsistent efficacy across trials, the absence of standardized protocols, and unresolved safety concerns. Emerging technologies, including stem cell-derived exosomes, gene-edited stem cells, and 3D liver organoids, show promising
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.